Physician profile
Kenneth E Stephens
NPI 1891760971
$475.57
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $197 · 2020: $152 · 2021: $126.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $70.93 | 2019-2021 | |
| Abbvie INC. | $45.70 | 2021 | |
| Melinta Therapeutics, LLC | $37.04 | 2019 | |
| Horizon Therapeutics Plc | $32.27 | 2021 | |
| Kerecis Limited | $30.28 | 2020 | |
| Smith+Nephew, INC. | $29.36 | 2020 | |
| Merck Sharp & Dohme LLC | $25.26 | 2019 | |
| Orthofix Medical, INC. | $23.45 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $22.26 | 2019 | |
| Pacira Therapeutics, INC. | $21.86 | 2019 | |
| Molnlycke Health Care US, LLC | $18.11 | 2020 | |
| Paragon 28, INC. | $16.91 | 2021 | |
| Bioventus LLC | $16.45 | 2019 | |
| Paratek Pharmaceuticals, INC. | $14.17 | 2019 | |
| Arthrosurface Incorporated | $14.12 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $13.78 | 2019 | |
| Ermi LLC | $12.62 | 2019 | |
| Depuy Synthes Sales INC. | $12.52 | 2020 | |
| Osteomed LLC | $12.25 | 2021 | |
| Reprise Biomedical, INC. | $6.23 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Stephens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.